Program
tradipitant
Also written as “Tradipitant”, “VLY-686” and “LY686017”.
Its studies are mostly in Motion Sickness · Gastroparesis · Dermatitis, Atopic · Pruritus · Nausea, led by 2 companies.
Drug pageTradipitant: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vanda Pharmaceuticalsits history only | 173 open or running | phase 3since Jun 13, 2018 | Aug 2, 2013 | Dec 1, 2026phase 3 · NCT07446439 |
| Eli Lilly | 20 open or running | phase 2since Sep 12, 2005 | Sep 12, 2005 | none ahead |
Also a collaborator on its studies: Cross Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Eli Lilly only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2005First study: phase 2 study in Phobia, SocialFirst studyNCT00191022 · 185 enrolled · United States
- Dec 5, 2008Phase 2 study in AlcoholismNCT00805441 · 190 enrolled · United States
TargetBeta
“An orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor; NK1R; NK-1R) antagonist ”NCIt, by rule
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aprepitantrule | Merck | phase 4 | 27 |
| elinzanetantrule | Bayer | phase 3 | 24 |
| fosnetupitantrule | Helsinn Healthcare | phase 3 | 2 |
| HRS5580 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 2 Eli Lilly leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00805441Alcoholism · United States | 2 | Completed | Jul 2009 | 190 |
| NCT00191022Phobia, Social · United States | 2 | Completed | 185 |
How it is read
Names in the registry
- “Tradipitant”, 13 entries
- “VLY-686”, 2 entries
- “LY686017”, 2 entries
- “Open Label Tradipitant”, 1 entry
- “VLY-686 (Tradipitant)”, 1 entry
Conditions, from the studies’ own filings
- Motion Sickness, 4 studies
- Gastroparesis, 3 studies
- Dermatitis, Atopic, 3 studies
- Pruritus, 2 studies
- Nausea, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.